港股異動 | 首款抗FcRn單抗獲FDA批准 再鼎醫藥高開8% 獲引進中國權益
格隆匯12月20日丨再鼎醫藥高開8.93%,報555港元,總市值535億港元。12月17日,Argenx宣佈,美國FDA批准VYVGART™(efgartigimod alfa-fcab)上市,用於治療抗乙酰膽鹼受體 (AChR) 抗體陽性的成人全身性重症肌無力 (gMG)。gMG是一種導致肌肉功能喪失的自身免疫性疾病。Efgartigimod是首個獲得FDA批准的抗FcRn單抗。2021年1月,再鼎醫藥與Argenx達成協議,獲得在大中華區獨家開發和商業化efgartigimod的權利。再鼎醫藥將負責efgartigimod多個適應症在中國的全球註冊臨牀研究開發工作。Argenx將獲得總計1.75億美元的合作付款,其中包括7,500萬美元的預付款,以每股132美元的價格發行的568,182股再鼎醫藥增發股票形式支付,7,500萬美元臨牀開發成本共擔付款,以及efgartigimod在美國獲批後的2,500萬美元的里程碑付款。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.